1. Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer

   • Jan Nyrop Jakobsen
   • Jens Benn Sørensen

   Mini Review 01 December 2011 Pages: 289 - 299

2. Oxidative damage to guanine nucleosides following combination chemotherapy with 5-fluorouracil and oxaliplatin

   • Shoaib Afzal
   • Søren Astrup Jensen
   • Henrik Enghusen Poulsen

   Original Article 28 June 2011 Pages: 301 - 307

3. Imatinib mesylate in thymic epithelial malignancies

   • Giovannella Palmieri
   • Mirella Marino
   • Vincenzo Damiano

   Original Article 28 June 2011 Pages: 309 - 315

   

4. Matrine induces caspase-dependent apoptosis in human osteosarcoma cells in vitro and in vivo through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2

   • Cheng Zhen Liang
   • Jia Kai Zhang
   • Hui Min Tao

   Original Article 30 June 2011 Pages: 317 - 331

   

5. Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors

   • B. Schultheis
   • G. Kummer
   • D. Strumberg

   Original Article 08 July 2011 Pages: 333 - 339

6. Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies

   • R. Thertulien
   • G. M. Manikhas
   • A. P. Staddon

   Original Article Open access 08 July 2011 Pages: 341 - 350

   

7. Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

   • Ioannis Boukovinas
   • Nikolaos Androulakis
   • Vassilis Georgoulias

   Original Article 12 July 2011 Pages: 351 - 356

   

8. Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy

   • Olivier Mir
   • Narjiss Berrada
   • Axel Le Cesne

   Original Article 19 July 2011 Pages: 357 - 367

9. A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer

   • Francesco Grossi
   • Filippo de Marinis
   • Enzo Galligioni

   Original Article 21 July 2011 Pages: 369 - 375

   

10. Inhibition of glutathione synthesis reverses Krüppel-like factor 4-mediated cisplatin resistance

    • Yongsheng Jia
    • Wenjian Zhang
    • Jinning Lou

    Original Article 22 July 2011 Pages: 377 - 385

    

11. Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study

    • Xiao-Jian Liu
    • Ye Guo
    • Xiao-Nan Hong

    Original Article 26 July 2011 Pages: 387 - 395

    

12. Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children

    • Gisela Kersting
    • Stefan Willmann
    • Georg Hempel

    Original Article 26 July 2011 Pages: 397 - 405

    

13. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)

    • Wasaburo Koizumi
    • Norisuke Nakayama
    • Chikatoshi Katada

    Original Article 28 July 2011 Pages: 407 - 413

    

14. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma

    • Ana De Jesus-Acosta
    • George R. Oliver
    • Luis A. Diaz Jr.

    Original Article Open access 29 July 2011 Pages: 415 - 424

    

15. The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis

    • Hassan K. Dakik
    • Daniel J. Moskovic
    • David R. Fogelman

    Original Article 18 August 2011 Pages: 425 - 430

    

16. Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors

    • Giovanna Speranza
    • Martin E. Gutierrez
    • Alice Chen

    Original Article 31 July 2011 Pages: 431 - 438

    

17. Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer

    • Taroh Satoh
    • Yasuhide Yamada
    • Narikazu Boku

    Original Article 19 August 2011 Pages: 439 - 446

    

18. Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation

    • Ines Paule
    • Michel Tod
    • Pascal Girard

    Original Article 02 August 2011 Pages: 447 - 455

    

19. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer

    • Masashi Ando
    • Kan Yonemori
    • Yasuhiro Fujiwara

    Original Article 19 August 2011 Pages: 457 - 465

    

20. Nucleoside transporters are widely expressed in ovarian carcinoma effusions

    • Annika J. Bock
    • Hiep Phuc Dong
    • Ben Davidson

    Original Article 06 August 2011 Pages: 467 - 475

    

21. Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study

    • N. Xenidis
    • L. Chelis
    • S. Kakolyris

    Original Article 20 August 2011 Pages: 477 - 484

    

22. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer

    • Xiangdong Ma
    • Jianfang Zhang
    • Detang Wang

    Original Article 13 August 2011 Pages: 485 - 494

    

23. Probenecid is a chemosensitizer in cancer cell lines

    • Denise Campos-Arroyo
    • Juan Carlos Martínez-Lazcano
    • Jorge Melendez-Zajgla

    Original Article 23 August 2011 Pages: 495 - 504

    

24. A phase I study of bortezomib and temozolomide in patients with advanced solid tumors

    • J. Portnow
    • P. Frankel
    • T. W. Synold

    Original Article 18 August 2011 Pages: 505 - 514

    

25. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study

    • Zhonghua Wang
    • Jingsong Lu
    • Xichun Hu

    Original Article 27 August 2011 Pages: 515 - 522

    

26. Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors

    • Elaine T. Lam
    • Sanjay Goel
    • Miguel A. Villalona-Calero

    Original Article 27 August 2011 Pages: 523 - 531

    

27. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial

    • P. Skarlos
    • C. Christodoulou
    • G. Fountzilas

    Original Article 08 September 2011 Pages: 533 - 546

    

28. A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies

    • Julie Bauman
    • Claire Verschraegen
    • Dennie Jones

    Original Article 08 September 2011 Pages: 547 - 554

29. The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer

    • Geoffrey I. Shapiro
    • Richard Frank
    • Lionel D. Lewis

    Clinical Trial Report 06 November 2011 Pages: 555 - 562

    

30. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer

    • Heather A. Wakelee
    • Chris H. Takimoto
    • Jordi Rodon

    Clinical Trial Report 06 November 2011 Pages: 563 - 571

    

31. Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane

    • Seppo W. Langer
    • Annemette V. Thougaard
    • Peter Buhl Jensen

    Short Communication 06 December 2011 Pages: 573 - 576